Turenne Capital, established in 2012, is a venture capital fund focusing on Series B investments in biotech and health tech sectors. They provide funding tailored to the needs of emerging companies. Notable investments include Antabio. Their aim is to support and grow promising enterprises with financial backing and strategic guidance.
